Cayuga Biotech: PolyP-SNP Data Shows 12x Faster Clotting in Fatal Hemorrhages Causing 2M Deaths Annually

Cayuga Biotech, a pharmaceutical company specializing in drugs that enhance the body's natural healing and bleeding control mechanisms, has showcased promising preclinical data for its innovative polyphosphate (polyP)-based therapy aimed at treating life-threatening hemorrhage. The results were unveiled at the Annual Meeting of the International Society for Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand.

The company's novel therapy, a polyP-SNP (silica nanoparticle) complex, demonstrated significant improvements in clotting capabilities when tested under both standard and lethal triad conditions in vitro and ex vivo. The therapy generated thrombin 12 times faster than the control, leading to quicker clot formation with a minimal risk of off-target thromboembolism. These findings were shared through both oral and poster presentations at the ISTH event.

James Morrissey, PhD, a Professor of Biological Chemistry and Internal Medicine at the University of Michigan and a study co-author, highlighted the significance of these results. According to Morrissey, the primary challenge with exogenous polyP has been its inability to be delivered systemically. However, the polyP-SNP complex successfully overcomes this limitation while showing superior clotting performance even under conditions that typically hinder the body's ability to stop bleeding, such as hemodilution, hypothermia, and acidosis.

In the ISTH session titled "New strategies for reversal and prevention of bleeding," data was presented demonstrating the polyP-SNP complex's ability to accelerate thrombin generation, which is crucial for effective clotting. As an injectable drug that remains inert in healthy tissues, the complex can circulate through the bloodstream to any bleeding site, accelerating the clotting response without promoting excessive clotting. The polyP-SNP complex acts independently of FXII activation, suggesting a low likelihood of causing clots in healthy tissue, a common issue with other injectable hemorrhage treatments.

Hemorrhage is a leading cause of preventable death worldwide, claiming nearly 2 million lives annually. Most of these deaths are due to non-compressible hemorrhage sites, such as internal bleeding or injuries from penetrating trauma, and the delays in achieving hemostatic control. These conditions are not adequately managed by current medical practices, making the development of more effective therapies crucial.

Cayuga Biotech is at the forefront of developing such therapies. Their polyP-SNP complex is in the late stages of preclinical development for treating acute major hemorrhage. Additionally, the company is working on a novel composition for inherited bleeding disorders and has a range of early-stage programs focused on various aspects of the healing process.

The company’s advancements could offer new hope for patients suffering from severe bleeding, potentially reducing the high mortality rate associated with hemorrhage. By leveraging the unique properties of inorganic polyphosphate, Cayuga Biotech aims to create therapies that not only enhance the body's natural clotting mechanisms but also minimize the risks associated with current treatment options.

In summary, Cayuga Biotech’s research and development efforts are paving the way for groundbreaking treatments in the field of hemorrhage and bleeding disorders. Their polyP-SNP complex shows promise in providing faster, more effective solutions for life-threatening bleeding conditions, addressing significant gaps in current medical care.